Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | BCL2 | P10415 | 3/20 | 0.40 |
| ▸ | BCL2L2 | Q92843 | 3/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21459810 | 1.00 | GCK (0.45) | GCKPTGS2BCL2BCL2L2MCL1 | |
| SCHEMBL21459812 | 1.00 | GCK (0.45) | GCKPTGS2BCL2BCL2L2MCL1 | |
| SCHEMBL21475918 | 0.85 | GCK (0.49) | GCKSLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL28511063 | 0.83 | MCL1 (0.47) | GCKPTGS2BCL2BCL2L2MCL1 | |
| SCHEMBL21459740 | 0.81 | SLC6A3 (0.41) | PTGS2SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL21459743 | 0.81 | SLC6A3 (0.41) | PTGS2SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL21459451 | 0.80 | PTGS2 (0.39) | PTGS2ALDH1A1CYP2C19 | |
| SCHEMBL21459789 | 0.80 | PSEN1 (0.44) | GCKPTGS2BCL2BCL2L2MCL1 | |
| SCHEMBL21459362 | 0.79 | BCL2 (0.47) | BCL2BCL2L2MCL1ALDH1A1 | |
| SCHEMBL21459361 | 0.79 | BCL2 (0.47) | BCL2BCL2L2MCL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | GCK 2641/4885PTGS2 4366/4885BCL2 4069/4885 |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | GCK 2881/4885PTGS2 4519/4885BCL2 4186/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | GCK 2641/4885PTGS2 4366/4885BCL2 4069/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | GCK 3465/4885PTGS2 4438/4885BCL2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.